Drug Overview
Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.
Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.
Table of Contents
1 Product Profiles- Invokana: Diabetic nephropathy
- Invokana: Diabetes type 2
List of Figures
Figure 1: Invokana for diabetic nephropathy - SWOT analysis
Figure 2: The author’s drug assessment summary for Invokana in diabetic nephropathy
Figure 3: The author’s drug assessment summary for Invokana in diabetic nephropathy
Figure 4: Invokana for type 2 diabetes - SWOT analysis
Figure 5: Drug assessment of Invokana
Figure 6: Drug assessment scorecard for Invokana compared to Januvia
Figure 7: Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
Figure 8: Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
List of Tables
Table 1: Invokana drug profile
Table 2: Invokana Phase III trial in diabetic nephropathy
Table 3: Invokana drug profile
Table 4: Overview of pivotal trial data for Invokana in diabetes
Table 5: Key endpoint data from the CANVAS trial program
Table 6: Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 7: Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Companies Mentioned
- Johnson & Johnson
- Mitsubishi Tanabe
- Daiichi Sankyo
